


Addressing Misconceptions in Obesity: Evidence-Based Treatment Approaches



REFERENCES:

Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. Jun 2022;2:100018. doi:10.1016/j.obpill.2022.100018

Bays HE, Golden A, Tondt J. Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. Sep 2022;3:100034. doi:10.1016/j.obpill.2022.100034

Benson-Davies S, Frederiksen K, Patel R. Bariatric Nutrition and Evaluation of the Metabolic Surgical Patient: Update to the 2022 Obesity Medicine Association (OMA) Bariatric Surgery, Gastrointestinal Hormones, and the Microbiome Clinical Practice Statement (CPS). *Obes Pillars*. March 2025;13:100154. doi:10.1016/j.obpill.2024.100154

Bersani FS, Coviello M, Imperatori C, et al. Adverse psychiatric effects associated with herbal weight-loss products. *Biomed Res Int*. 2015;120679. doi:10.1155/2015/120679

Bray GA, Kim KK, Wilding JPH. Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes Rev*. Jul 2017;18(7):715-723. doi:10.1111/obr.12551

Casazza K, Pate R, Allison DB. Myths, presumptions, and facts about obesity. *N Engl J Med*. Jun 6 2013;368(23):2236-2237. doi:10.1056/NEJMc1303009

Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. *Surg Obes Relat Dis*. Dec 2022;18(12):1345-1356. doi:10.1016/j.soard.2022.08.013

Fischer NM, Pallazola VA, Xun H, Cainzos-Achirica M, Michos ED. The evolution of the heart-healthy diet for vascular health: A walk through time. *Vasc Med*. Apr 2020;25(2):184-193. doi:10.1177/1358863x19901287

Fitch AK, Auriemma A, Bays HE. Compounded peptides: An Obesity Medicine Association Position Statement. *Obes Pillars*. 2023;6:100061. doi:10.1016/j.obpill.2023.100061

Fitch AK, Alexander L, Brown CF, Bays HE. Comprehensive care for patients with obesity: An obesity medicine association position statement. *Obes Pillars*. May 2023;7:100070. doi:10.1016/j.obpill.2023.100070


Fitch AK, Bays HE. Obesity Definition, Diagnosis, Bias, Standard Operating Procedures (SOPs), and Telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. Mar 2022;1:100004. doi:10.1016/j.obpill.2021.100004

Freshwater M, Christensen S, Oshman L, Bays HE. Behavior, Motivational Interviewing, Eating Disorders, and Obesity Management Technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. June 2022;2:100014. doi:https://doi.org/10.1016/j.obpill.2022.100014

Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. *J Am Assoc Nurse Pract*. Oct 2017;29(S1):S3-s14. doi:10.1002/2327-6924.12510


Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet*. Apr 16 2011;377(9774):1341-1352. doi:10.1016/s0140-6736(11)60205-5

Addressing Misconceptions in Obesity: Evidence-Based Treatment Approaches



- Gasoyan H, Tajeu G, Halpern MT, Sarwer DB. Reasons for underutilization of bariatric surgery: The role of insurance benefit design. *Surg Obes Relat Dis*. Jan 2019;15(1):146-151. doi:<https://doi.org/10.1016/j.soard.2018.10.005>
- Ginsburg BM, Daley SF, Sheer AJ. Overcoming stigma and bias in obesity management. *StatPearls*. Treasure Island (FL): StatPearls Publishing; March 2024.
- Gordon ML, Althoff T, Leskovec J. Goal-setting And Achievement In Activity Tracking Apps: A Case Study Of MyFitnessPal. *Proc Int World Wide Web Conf*. May 2019;2019:571-582. doi:10.1145/3308558.3313432
- Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. Aug 21 2010;376(9741):595-605. doi:10.1016/s0140-6736(10)60888-4
- Grunvald E, Shah R, Hernaez R, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. *Gastroenterol*. Nov 2022;163(5):1198-1225. doi:10.1053/j.gastro.2022.08.045
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. Jul 21 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. Jun 2004;89(6):2548-2556. doi:10.1210/jc.2004-0395
- Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: Evolving policies and their implications. *Endocrinol Metab Clin North Am*. Sep 2016;45(3):511-520. doi:10.1016/j.ecl.2016.04.004
- Ostrominski JW, Zelle D, Unlu O, et al. Contemporary prevalence, comorbidity burden, and treatment of overweight and obesity: Insights from the multicenter Mass General Brigham Healthcare System. Presented at: American Heart Association's (AHA) 2023 Scientific Sessions. November 11-13, 2023; Philadelphia, PA. https://www.cardiometabolichealth.org/wp-content/uploads/2024/10/2_CMHC-24_SAIL-Phase-1-poster_10.11.2024-FINAL.pdf
- Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton Obesity Staging System to predict mortality in a population-representative cohort of people with overweight and obesity. *CMAJ*. Oct 4 2011;183(14):E1059-1066. doi:10.1503/cmaj.110387
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*. Jul 2 2015;373(1):11-22. doi:10.1056/NEJMoa1411892
- Ramachandran B, Jayavelu S, Murhekar K, Rajkumar T. Repeated dose studies with pure Epigallocatechin-3-gallate demonstrated dose and route dependant hepatotoxicity with associated dyslipidemia. *Toxicol Rep*. 2016;3:336-345. doi:10.1016/j.toxrep.2016.03.001
- Roerig JL, Steffen KJ, Mitchell JE, Zunker C. Laxative abuse: epidemiology, diagnosis and management. *Drugs*. Aug 20 2010;70(12):1487-1503. doi:10.2165/11898640-000000000-00000
- Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. *Curr Obes Rep*. Jun 2017;6(2):187-194. doi:10.1007/s13679-017-0262-y

Addressing Misconceptions in Obesity: Evidence-Based Treatment Approaches



Sharma AM, Kushner RF. A proposed clinical staging system for obesity. *Int J Obes (Lond)*. Mar 2009;33(3):289-295. doi:10.1038/ijo.2009.2

Shetye B, Hamilton FR, Bays HE. Bariatric Surgery, Gastrointestinal Hormones, and the Microbiome: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. Jun 2022;2:100015. doi:10.1016/j.obpill.2022.100015

Tirzepatide (Mounjaro®). Prescribing Information. Eli Lilly and Company; 2024.

Tondt J, Bays HE. Concomitant Medications, Functional Foods, and Supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. Jun 2022;2:100017. doi:10.1016/j.obpill.2022.100017

Tondt J, Freshwater M, Christensen S, et al. Obesity algorithm slides, presented by the Obesity Medicine Association. Published 2023; Accessed November 13, 2024. <https://obesitymedicine.org/obesity-algorithm-powerpoint>

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. Mar 18 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. *J Hypertens*. Dec 1998;16(12 Pt 2):2013-7. doi:10.1097/00004872-199816121-00024